176
Participants
Start Date
November 30, 2013
Primary Completion Date
July 31, 2016
Study Completion Date
September 30, 2016
Revlimid (lenalidomide)
Revlimid (lenalidomide) as prescribed in usual clinical practice
Peking Chao-Yang Hospital, Beijing
Peking University People's Hospital, Beijing
People's Liberation Army Hospital 307, Beijing
Beijing Hospital, Beijing
The Second Affiliated Hospital Of China Medical University, Shenyang
The Fisrt Hospital Of Jilin University, Changchun
Shanghai Changzhen Hospital, Shanghai
The First Affiliated Hospital of Suzhou University, Suzhou
The First Affliated Hospital of Anhui Medical University, Hefei
Qilu Hospital of Shandong University, Jinan
The Affiliated Hospital of Mecical College Qingdao University, Qingdao
Xiangya Hospital Central-South University, Changsha
Xinqiao Hospital, 3rd Military Medical University, Chongqing
Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science & Technology, Wuhan
Tongji Medical College Huazhong University of Science & Technology, Wuhan
NanFang Hospital of China Southern Medical University, Guangzhou
People's Hospital of Xinjiang Uygur Autonomous Region, Ürümqi
Lead Sponsor
Celgene
INDUSTRY